| · | MBA from Zhongnan University of Economics and Law and an EMBA from Cheung Kong Graduate School of Business.
|
| · | A key member of the investment committee of China Pharmaceutical Innovation and Research Development Association ,a member of Bayhelix Group.
|
| · | Selected as the ' Most Promising Investor in Shenzhen', 'China Finance Person of The Year 2019', 'China's Best New Venture Capital Manager in 2018' |
| · | Efung has beenrated as “Shenzhen Top Ten Venture Capital Institutions“ and “Shenzhen Best Innovative Financial Institution” for many years. |
| · | Over 19 years of experience in life science investment. |
| · | Has invested more than 20 domestic and oversea enterprises such as Mindray Medical , ChipScreen , Frontier Biotechnologies , Ascentage Pharma , Lifotronic , HaploX, Resverlogix, Centrexion Therapeutics, Apexigen and etc. |